[Paion] Ferric Citrate, the Active Ingredient for Kidney Disease Drug, Approved for Market Entry in China by NMPA
Paion Biotech announced that the Chinese National Medical Products Administration (NMPA) has approved the market registration of Ferric Citrate, the primary active ingredient for its kidney disease drug, Nephoxil. This strengthens the company's supply chain and deepens its vertical integration strategy.
📋 Article Processing Timeline
- 📰 Published: May 21, 2026 at 09:00
- 🔍 Collected: May 22, 2026 at 08:00 (23h 0m after Published)
- 🤖 AI Analyzed: May 22, 2026 at 08:41 (41 min after Collected)
1. Date of Occurrence: May 21, 115
2. Company Name: Paion Biotech Co., Ltd.
3. Relationship to the Company (Input Parent Company or Subsidiary): Parent Company
4. Mutual Shareholding Ratio: Not applicable
5. Reason for Occurrence: The primary active ingredient, Ferric Citrate (generic name in China: Ferric Citrate), for our company's new kidney disease drug, Nephoxil 500mg Capsule, has been reviewed and approved for market registration by the China National Medical Products Administration (NMPA).
6. Response: Disclosure of material information
7. Other relevant information (If the subject of the event or resolution is a public offering company or higher, this material information is deemed to have a significant impact on shareholder rights or securities prices pursuant to Article 7, Paragraph 9 of the Securities Trading Act Enforcement Rules):
(1) Ferric Citrate is the primary ingredient for our kidney disease drug, Nephoxil. Obtaining approval for this active ingredient in China helps strengthen the supply chain for Nephoxil in the Chinese market and deepens our strategy for vertical integration of active ingredients.
(2) The subject of this approval is the active ingredient (Ferric Citrate). This is separate from the market approval for the Nephoxil 500mg Capsule drug product announced on April 27, 115, as they fall under individual inspection and registration procedures. This announcement discloses the approval concerning the active ingredient.
(3) New drug development is a long-term process requiring significant investment without guaranteed success; investors should exercise prudent judgment.
2. Company Name: Paion Biotech Co., Ltd.
3. Relationship to the Company (Input Parent Company or Subsidiary): Parent Company
4. Mutual Shareholding Ratio: Not applicable
5. Reason for Occurrence: The primary active ingredient, Ferric Citrate (generic name in China: Ferric Citrate), for our company's new kidney disease drug, Nephoxil 500mg Capsule, has been reviewed and approved for market registration by the China National Medical Products Administration (NMPA).
6. Response: Disclosure of material information
7. Other relevant information (If the subject of the event or resolution is a public offering company or higher, this material information is deemed to have a significant impact on shareholder rights or securities prices pursuant to Article 7, Paragraph 9 of the Securities Trading Act Enforcement Rules):
(1) Ferric Citrate is the primary ingredient for our kidney disease drug, Nephoxil. Obtaining approval for this active ingredient in China helps strengthen the supply chain for Nephoxil in the Chinese market and deepens our strategy for vertical integration of active ingredients.
(2) The subject of this approval is the active ingredient (Ferric Citrate). This is separate from the market approval for the Nephoxil 500mg Capsule drug product announced on April 27, 115, as they fall under individual inspection and registration procedures. This announcement discloses the approval concerning the active ingredient.
(3) New drug development is a long-term process requiring significant investment without guaranteed success; investors should exercise prudent judgment.
FAQ
What is Nephoxil, the drug developed by Paion?
It is a medication for kidney disease. This announcement specifically concerns the NMPA approval of its active ingredient, Ferric Citrate, in China.
Is this news significant for investors?
Yes, as it solidifies the company's supply chain and competitive position in the lucrative Chinese market, representing a key strategic milestone.
Why is the approval of the API (Active Pharmaceutical Ingredient) important?
Securing API approval allows for vertical integration, ensuring cost-effectiveness and supply stability, which are critical for long-term growth in the Chinese market.